Wall Street Zen Downgrades Kestra Medical Technologies (NASDAQ:KMTS) to Sell

Kestra Medical Technologies (NASDAQ:KMTS) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Other analysts have also recently issued reports about the company. BTIG Research boosted their price objective on Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Wolfe Research set a $30.00 price target on shares of Kestra Medical Technologies in a research report on Wednesday. Weiss Ratings downgraded shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. Finally, The Goldman Sachs Group cut their price objective on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $27.83.

Kestra Medical Technologies Stock Performance

KMTS stock opened at $24.42 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.41 and a quick ratio of 4.41. The company has a 50 day moving average price of $22.28 and a 200 day moving average price of $22.69. Kestra Medical Technologies has a fifty-two week low of $14.10 and a fifty-two week high of $30.00. The stock has a market capitalization of $1.43 billion, a PE ratio of -10.09 and a beta of 0.47.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). The firm had revenue of $28.64 million during the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. Analysts forecast that Kestra Medical Technologies will post -2.3 EPS for the current year.

Insiders Place Their Bets

In related news, insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $20.81, for a total value of $312,150.00. Following the sale, the insider directly owned 395,467 shares in the company, valued at $8,229,668.27. This trade represents a 3.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 3.60% of the company’s stock.

Institutional Investors Weigh In On Kestra Medical Technologies

Large investors have recently modified their holdings of the business. Millennium Management LLC acquired a new stake in shares of Kestra Medical Technologies during the first quarter worth about $11,036,000. Woodline Partners LP acquired a new position in shares of Kestra Medical Technologies in the 1st quarter valued at approximately $2,510,000. Jane Street Group LLC bought a new stake in Kestra Medical Technologies during the 1st quarter worth approximately $756,000. Geode Capital Management LLC raised its holdings in Kestra Medical Technologies by 718.5% during the 2nd quarter. Geode Capital Management LLC now owns 325,326 shares of the company’s stock worth $5,395,000 after buying an additional 285,579 shares during the period. Finally, JPMorgan Chase & Co. acquired a new stake in Kestra Medical Technologies during the 2nd quarter worth approximately $256,000.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.